THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [12.26]-CMP170 ID: TIP-MED-000440

Mometasone Furoate 0.1%, Tacrolimus 0.03%/0.1% Ointment, Calcipotriol & Salicylic Acid / Coal Tar

Active Ingredient / Scientific Identity: Mometasone Furoate 0.1%, Tacrolimus 0.03%/0.1% Ointment, Calcipotriol & Salicylic Acid / Coal Tar • Class: Potent (Class II/III) Fluorinated Topical Corticosteroid

⚖️ Compare Profile
Generic / Entity NameMometasone Furoate 0.1%, Tacrolimus 0.03%/0.1% Ointment, Calcipotriol & Salicylic Acid / Coal Tar ([12.26]-CMP170)
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassPotent (Class II/III) Fluorinated Topical Corticosteroid
Available Dosage FormsStandard approved strengths (refer to comparative context)
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: No adjustment. • Hepatic: Extensive systemic absorption over large body surface area in liver failure can cause HPA ax
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Mometasone Furoate 0.1%, Tacrolimus 0.03%/0.1% Ointment, Calcipotriol & Salicylic Acid / Coal Tar (TIP-MED-000440, Reference Code [12.26]-CMP170) is classified under Dermatological & Topical Antiseptic Preparations (Ch 12) as a Potent (Class II/III) Fluorinated Topical Corticosteroid. Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Co-indexed per approved Author Decisions DEC-09 (9A; from displaced HTML [12.28]) and DEC-12 (12A; from HTML [12.23] & Inventory CSV mono-14-3). Medium-potency topical steroid, steroid-sparing topical calcineurin inhibitor, vitamin D3 psoriasis analogue, and keratolytics.
Co-indexed per approved Author Decisions DEC-09 (9A; from displaced HTML [12.28]) and DEC-12 (12A; from HTML [12.23] & Inventory CSV mono-14-3). Medium-potency topical steroid, steroid-sparing topical calcineurin inhibitor, vitamin D3 psoriasis analogue, and keratolytics.
Dosage Forms & Available Strengths:
Standard approved strengths (refer to comparative context)
Routes: Oral / Parenteral

3. Mechanism of Action & Pharmacodynamics

Co-indexed per approved Author Decisions DEC-09 (9A; from displaced HTML [12.28]) and DEC-12 (12A; from HTML [12.23] & Inventory CSV mono-14-3). Medium-potency topical steroid, steroid-sparing topical calcineurin inhibitor, vitamin D3 psoriasis analogue, and keratolytics.

4. Therapeutic Indications & Evidence-Supported Uses

  • Steroid-responsive inflammatory dermatoses: chronic plaque psoriasis, lichen planus, severe atopic/nummular eczema, contact dermatitis, discoid lupus erythematosus

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Co-indexed per approved Author Decisions DEC-09 (9A; from displaced HTML [12.28]) and DEC-12 (12A; from HTML [12.23] & Inventory CSV mono-14-3). Medium-potency topical steroid, steroid-sparing topical calcineurin inhibitor, vitamin D3 psoriasis analogue, and keratolytics.

Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Comparative pharmacokinetic profile co-indexed under [12.26].
Metabolism & Biotransformation:
Renal: No adjustment. • Hepatic: Extensive systemic absorption over large body surface area in liver failure can cause HPA axis suppression.
Elimination & Renal Adjustment:
Renal: No adjustment. • Hepatic: Extensive systemic absorption over large body surface area in liver failure can cause HPA axis suppression.
Hepatic Impairment Considerations:
Renal: No adjustment. • Hepatic: Extensive systemic absorption over large body surface area in liver failure can cause HPA axis suppression.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindications: Untreated cutaneous bacterial, viral (herpes simplex, varicella), or fungal (tinea) infections; rosacea; acne vulgaris; perioral dermatitis; routine use on face, groin, or axillae. • Precautions: SEVERE TOPICAL STEROID MISUSE EPIDEMIC IN INDIA: Never dispense or recommend Betnovate as a fairness cream, acne cream, or groin ringworm cream—facial/intertriginous use causes irreversible skin atrophy, telangiectasia, steroid rosacea, perioral dermatitis, hypertrichosis, and tinea incognito! Application of >50 g/week or under occlusive dressings suppresses the hypothalamic-pituitary-adrenal (HPA) axis and causes iatrogenic Cushing's syndrome.

Key Clinical Precautions: Renal: No adjustment. • Hepatic: Extensive systemic absorption over large body surface area in liver failure can cause HPA axis suppression.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Skin thinning (epidermal/dermal atrophy), striae distensae (stretch marks), telangiectasia, hypopigmentation, contact folliculitis.
  • Adrenal suppression / Cushing's syndrome (extensive/occluded use), glaucoma/cataracts (periocular application), rebound pustular psoriasis on abrupt cessation.
Serious / Dose-Limiting Adverse Effects:

    9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

    • Concurrent systemic corticosteroids -> additive HPA axis suppression

    10. Clinical Monitoring, Patient Counselling & Storage

    Clinical & Laboratory Monitoring: Monitor clinical parameters per parent class monograph [12.26].

    Pharmacist Patient Counselling Points:

    • Patient Counselling Checklist: Use the Finger-Tip Unit (FTU) rule to apply a very thin layer to the affected eczema/psoriasis patch only; NEVER apply on the face, groin, or fungal ringworm; apply moisturisers 30 minutes apart.
    • Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
    • Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
    • Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Yes | Compendia: IP 2026 / NFI 7th Ed 2026 / NLEM 2022 / CDSCO Schedule H / BNF 90th Ed

    Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Cream / Ointment / Scalp Lotion: Betamethasone Valerate 0.1% w/w; Betamethasone Dipropionate 0.05% w/w (alone or with Salicylic Acid 3% for hyperkeratotic plaques).

    11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

    THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
    svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

    12. Authoritative References, Regulatory Sources & Editorial Disclaimer

    Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO

    Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

    Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

    Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.